A free agent after last July's $704 million buyout of Trius Therapeutics Inc., former CEO Jeffrey Stein was "approached with numerous opportunities" before choosing the earliest-stage prospect and "by far the most exciting one" in antifungals start-up Cidara Therapeutics Inc., he said.